Endostatin specifically targets both tumor blood vessels and lymphatic vessels

doi:10.1007/s11684-011-0163-5

Front Med

2011, Vol. 5

Issue (4) : 336-340 https://doi.org/10.1007/s11684-011-0163-5

MINI-REVIEW

Endostatin specifically targets both tumor blood vessels and lymphatic vessels

Wei Zhuo^1,2,3, Yang Chen^1,2,3, Xiaomin Song^1,2,3, Yongzhang Luo^1,2,3(

)

1. National Engineering Laboratory for Anti-tumor Protein Therapeutics, Beijing 100084, China; 2. Beijing Key Laboratory for Protein Therapeutics, Beijing 100084, China; 3. Cancer Biology Laboratory, School of Life Sciences, Tsinghua University, Beijing 100084, China

Download: PDF(141 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Endostatin, a 20 kDa C-terminal fragment of collagen XVIII, was first identified as a potent angiogenic inhibitor. The anti-angiogenic function of endostatin has been well documented during the past decade. Recently, several studies demonstrated that endostatin also inhibits tumor lymphangiogenesis and lymphatic metastasis. However, the exact mechanism that endostatin executes its anti-angiogenic and anti-lymphangiogenic functions remains elusive. In the current mini-review, we briefly summarize recent novel findings, including the functions of endostatin targeting not only angiogenesis but also lymphangiogenesis, and the underlying mechanism by which endostatin internalization regulates its biological functions.

Keywords endostatin angiogenesis lymphangiogenesis nystatin internalization tumor

Corresponding Author(s): Luo Yongzhang,Email:yluo@tsinghua.edu.cn

Issue Date: 05 December 2011

Cite this article:

Wei Zhuo,Yang Chen,Xiaomin Song, et al. Endostatin specifically targets both tumor blood vessels and lymphatic vessels[J]. Front Med, 2011, 5(4): 336-340.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-011-0163-5
https://academic.hep.com.cn/fmd/EN/Y2011/V5/I4/336

Fig.1 Two endocytic pathways are involved in endostatin internalization. One is the low-efficient caveola/lipid raft pathway, and the other is the high-efficient clathrin pathway. Nystatin treatment facilitates the translocation of endostatin out of caveola/lipid raft and switches endostatin internalization predominantly to the high-efficient clathrin-dependent pathway, resulting in enhanced endostatin overall uptake.

1	O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88(2): 277–285 doi: 10.1016/S0092-8674(00)81848-6 pmid:9008168
2	Folkman J. Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action. Exp Cell Res 2006; 312(5): 594–607 doi: 10.1016/j.yexcr.2005.11.015 pmid:16376330
3	Fu Y, Chen Y, Luo X, Liang Y, Shi H, Gao L, Zhan S, Zhou D, Luo Y. The heparin binding motif of endostatin mediates its interaction with receptor nucleolin. Biochemistry 2009; 48(49): 11655–11663 doi: 10.1021/bi901265z pmid:19877579
4	Fu Y, Luo Y. The N-terminal integrity is critical for the stability and biological functions of endostatin. Biochemistry 2010; 49(30): 6420–6429 doi: 10.1021/bi100489x pmid:20545324
5	Fu Y, Tang H, Huang Y, Song N, Luo Y. Unraveling the mysteries of endostatin. IUBMB Life 2009; 61(6): 613–626 doi: 10.1002/iub.215 pmid:19472178
6	Fukumoto S, Morifuji M, Katakura Y, Ohishi M, Nakamura S. Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis 2005; 22(1): 31–38 doi: 10.1007/s10585-005-3973-5 pmid:16132576
7	Brideau G, M?kinen MJ, Elamaa H, Tu H, Nilsson G, Alitalo K, Pihlajaniemi T, Heljasvaara R. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 2007; 67(24): 11528–11535 doi: 10.1158/0008-5472.CAN-07-1458 pmid:18089781
8	Zhuo W, Luo C, Wang X, Song X, Fu Y, Luo Y. Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells. J Pathol 2010; 222(3): 249–260 doi: 10.1002/path.2760 pmid:20814900
9	Ou J, Li J, Pan F, Xie G, Zhou Q, Huang H, Liang H. Endostatin suppresses colorectal tumor-induced lymphangiogenesis by inhibiting expression of fibronectin extra domain A and integrin α9. J Cell Biochem 2011; 112(8): 2106–2114 doi: 10.1002/jcb.23130 pmid:21465533
10	Achen MG, McColl BK, Stacker SA. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 2005; 7(2): 121–127 doi: 10.1016/j.ccr.2005.01.017 pmid:15710325
11	Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005; 438(7070): 946–953 doi: 10.1038/nature04480 pmid:16355212
12	Karpanen T, Alitalo K. Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol 2008; 3(1): 367–397 doi: 10.1146/annurev.pathmechdis.3.121806.151515 pmid:18039141
13	Cao R, Bj?rndahl MA, Religa P, Clasper S, Garvin S, Galter D, Meister B, Ikomi F, Tritsaris K, Dissing S, Ohhashi T, Jackson DG, Cao Y. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004; 6(4): 333–345 doi: 10.1016/j.ccr.2004.08.034 pmid:15488757
14	Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 2005; 24(16): 2885–2895 doi: 10.1038/sj.emboj.7600763 pmid:16052207
15	Bj?rndahl M, Cao R, Nissen LJ, Clasper S, Johnson LA, Xue Y, Zhou Z, Jackson D, Hansen AJ, Cao Y. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 2005; 102(43): 15593–15598 doi: 10.1073/pnas.0507865102 pmid:16230630
16	Chang LK, Garcia-Carde?a G, Farnebo F, Fannon M, Chen EJ, Butterfield C, Moses MA, Mulligan RC, Folkman J, Kaipainen A. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci USA 2004; 101(32): 11658–11663 doi: 10.1073/pnas.0404272101 pmid:15289610
17	Shi H, Huang Y, Zhou H, Song X, Yuan S, Fu Y, Luo Y. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007; 110(8): 2899–2906 doi: 10.1182/blood-2007-01-064428 pmid:17615292
18	Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engstr?m A, Timpl R, Welsh M, Claesson-Welsh L. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000; 95(11): 3403–3411 pmid:10828022
19	MacDonald NJ, Shivers WY, Narum DL, Plum SM, Wingard JN, Fuhrmann SR, Liang H, Holland-Linn J, Chen DH, Sim BK. Endostatin binds tropomyosin: a potential modulator of the antitumor activity of endostatin. J Biol Chem 2001; 276(27): 25190–25196 doi: 10.1074/jbc.M100743200 pmid:11335715
20	Zhou H, Wang W, Luo Y. Contributions of disulfide bonds in a nested pattern to the structure, stability, and biological functions of endostatin. J Biol Chem 2005; 280(12): 11303–11312 doi: 10.1074/jbc.M412072200 pmid:15634676
21	Le Roy C, Wrana JL. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 2005; 6(2): 112–126 doi: 10.1038/nrm1571 pmid:15687999
22	Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007; 8(3): 185–194 doi: 10.1038/nrm2122 pmid:17318224
23	Pellinen T, Tuomi S, Arjonen A, Wolf M, Edgren H, Meyer H, Grosse R, Kitzing T, Rantala JK, Kallioniemi O, F?ssler R, Kallio M, Ivaska J. Integrin trafficking regulated by Rab21 is necessary for cytokinesis. Dev Cell 2008; 15(3): 371–385 doi: 10.1016/j.devcel.2008.08.001 pmid:18804435
24	Shi F, Sottile J. Caveolin-1-dependent beta1 integrin endocytosis is a critical regulator of fibronectin turnover. J Cell Sci 2008; 121(14): 2360–2371 doi: 10.1242/jcs.014977 pmid:18577581
25	Caswell PT, Vadrevu S, Norman JC. Integrins: masters and slaves of endocytic transport. Nat Rev Mol Cell Biol 2009; 10(12): 843–853 doi: 10.1038/nrm2799 pmid:19904298
26	Chen Y, Wang S, Lu X, Zhang H, Fu Y, Luo Y. Cholesterol sequestration by nystatin enhances the uptake and activity of endostatin in endothelium via regulating distinct endocytic pathways. Blood 2011; 117(23): 6392–6403 doi: 10.1182/blood-2010-12-322867 pmid:21482707
27	Abdollahi A, Hahnfeldt P, Maercker C, Gr?ne HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE. Endostatin’s antiangiogenic signaling network. Mol Cell 2004; 13(5): 649–663 doi: 10.1016/S1097-2765(04)00102-9 pmid:15023336
28	Bazigou E, Xie S, Chen C, Weston A, Miura N, Sorokin L, Adams R, Muro AF, Sheppard D, Makinen T. Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis. Dev Cell 2009; 17(2): 175–186 doi: 10.1016/j.devcel.2009.06.017 pmid:19686679
29	Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003; 163(4): 871–878 doi: 10.1083/jcb.200304132 pmid:14638862
30	Huang Y, Shi H, Zhou H, Song X, Yuan S, Luo Y. The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 2006; 107(9): 3564–3571 doi: 10.1182/blood-2005-07-2961 pmid:16403913
31	Boehm T, Folkman J, Browder T, O’Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390(6658): 404–407 doi: 10.1038/37126 pmid:9389480
32	Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O’Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002; 20(18): 3792–3803 doi: 10.1200/JCO.2002.11.061 pmid:12228199
33	Dong X, Zhao X, Xiao T, Tian H, Yun C. Endostar, a recombined humanized endostatin, inhibits lymphangiogenesis and lymphatic metastasis of Lewis lung carcinoma xenograft in mice. Thorac Cardiovasc Surg 2011; 59(3): 133–136 doi: 10.1055/s-0030-1250152 pmid:21480131
34	Jia Y, Liu M, Huang W, Wang Z, He Y, Wu J, Ren S, Ju Y, Geng R, Li Z.Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer. Pathol Oncol Res 2011Sep 22. [Epub ahead of print] pmid:21938482
35	Albuquerque RJ, Hayashi T, Cho WG, Kleinman ME, Dridi S, Takeda A, Baffi JZ, Yamada K, Kaneko H, Green MG, Chappell J, Wilting J, Weich HA, Yamagami S, Amano S, Mizuki N, Alexander JS, Peterson ML, Brekken RA, Hirashima M, Capoor S, Usui T, Ambati BK, Ambati J. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009; 15(9): 1023–1030 doi: 10.1038/nm.2018 pmid:19668192
36	Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo C, Pihlajaniemi T, Alitalo K, Vuori K. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001; 98(3): 1024–1029 doi: 10.1073/pnas.031564998 pmid:11158588
37	Karumanchi SA, Jha V, Ramchandran R, Karihaloo A, Tsiokas L, Chan B, Dhanabal M, Hanai JI, Venkataraman G, Shriver Z, Keiser N, Kalluri R, Zeng H, Mukhopadhyay D, Chen RL, Lander AD, Hagihara K, Yamaguchi Y, Sasisekharan R, Cantley L, Sukhatme VP. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 2001; 7(4): 811–822 doi: 10.1016/S1097-2765(01)00225-8 pmid:11336704
38	Sasaki T, Fukai N, Mann K, G?hring W, Olsen BR, Timpl R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 1998; 17(15): 4249–4256 doi: 10.1093/emboj/17.15.4249 pmid:9687493
39	Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST, Kwon YG. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000; 60(19): 5410–5413 pmid:11034081
40	Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA 2003; 100(8): 4766–4771 doi: 10.1073/pnas.0730882100 pmid:12682293
41	Wickstr?m SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002; 62(19): 5580–5589 pmid:12359771
42	Wickstr?m SA, Alitalo K, Keski-Oja J. Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity. J Biol Chem 2003; 278(39): 37895–37901 doi: 10.1074/jbc.M303569200 pmid:12851410
43	Anderson RG. The caveolae membrane system. Annu Rev Biochem 1998; 67(1): 199–225 doi: 10.1146/annurev.biochem.67.1.199 pmid:9759488
44	Zhang AY, Yi F, Zhang G, Gulbins E, Li PL. Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. Hypertension 2006; 47(1): 74–80 doi: 10.1161/10.1161/01.HYP.0000196727.53300.62 pmid:16344372
45	Jin S, Zhang Y, Yi F, Li PL. Critical role of lipid raft redox signaling platforms in endostatin-induced coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol 2008; 28(3): 485–490 doi: 10.1161/ATVBAHA.107.159772 pmid:18162606
46	Said EA, Krust B, Nisole S, Svab J, Briand JP, Hovanessian AG. The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor. J Biol Chem 2002; 277(40): 37492–37502 doi: 10.1074/jbc.M201194200 pmid:12147681
47	Legrand D, Vigié K, Said EA, Elass E, Masson M, Slomianny MC, Carpentier M, Briand JP, Mazurier J, Hovanessian AG. Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. Eur J Biochem 2004; 271(2): 303–317 doi: 10.1046/j.1432-1033.2003.03929.x pmid:14717698

[1]	Xiaojing Jiao, Dong Zhang, Quan Hong, Lei Yan, Qiuxia Han, Fengmin Shao, Guangyan Cai, Xiangmei Chen, Hanyu Zhu. Netrin-1 works with UNC5B to regulate angiogenesis in diabetic kidney disease[J]. Front. Med., 2020, 14(3): 293-304.
[2]	Amy Lee, Fa-Chyi Lee. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check[J]. Front. Med., 2020, 14(3): 273-283.
[3]	Anqi Chen, Suhua Zhang, Jixi Li, Chaoneng Ji, Jinzhong Chen, Chengtao Li. Detecting genetic hypermutability of gastrointestinal tumor by using a forensic STR kit[J]. Front. Med., 2020, 14(1): 101-111.
[4]	Rui Zhou, Yuanshu Liu, Wenjun Huang, Xitong Dang. Potential functions of esophageal cancer-related gene-4 in the cardiovascular system[J]. Front. Med., 2019, 13(6): 639-645.
[5]	Xin Qin, Ping Zhang. ECRG4: a new potential target in precision medicine[J]. Front. Med., 2019, 13(5): 540-546.
[6]	Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy[J]. Front. Med., 2019, 13(1): 57-68.
[7]	Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian. Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy[J]. Front. Med., 2019, 13(1): 32-44.
[8]	Yinlong Zhang, Guangna Liu, Jingyan Wei, Guangjun Nie. Platelet membrane-based and tumor-associated platelet- targeted drug delivery systems for cancer therapy[J]. Front. Med., 2018, 12(6): 667-677.
[9]	Bin Yang, Yan Yu, Jing Chen, Yan Zhang, Ye Yin, Nan Yu, Ge Chen, Shifei Zhu, Haiyan Huang, Yongqun Yuan, Jihui Ai, Xinyu Wang, Kezhen Li. Possibility of women treated with fertility-sparing surgery for non-epithelial ovarian tumors to safely and successfully become pregnant---a Chinese retrospective cohort study among 148 cases[J]. Front. Med., 2018, 12(5): 509-517.
[10]	Lan Yu, Xun Tian, Chun Gao, Ping Wu, Liming Wang, Bei Feng, Xiaomin Li, Hui Wang, Ding Ma, Zheng Hu. Genome editing for the treatment of tumorigenic viral infections and virus-related carcinomas[J]. Front. Med., 2018, 12(5): 497-508.
[11]	Sumedha Roy, Yuan Zhuang. Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells[J]. Front. Med., 2018, 12(4): 374-386.
[12]	Minhong Shen, Yibin Kang. Complex interplay between tumor microenvironment and cancer therapy[J]. Front. Med., 2018, 12(4): 426-439.
[13]	Junyun Wang, Shuang Chang, Guochao Li, Yingli Sun. Application of liquid biopsy in precision medicine: opportunities and challenges[J]. Front. Med., 2017, 11(4): 522-527.
[14]	Zhen Zhang, Na Jiang, Zhaohui Ni. Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis[J]. Front. Med., 2017, 11(3): 349-358.
[15]	Hongli Yin,Tianyi Liu,Ying Zhang,Baofeng Yang. Caveolin proteins: a molecular insight into disease[J]. Front. Med., 2016, 10(4): 397-404.

Viewed

Full text

Abstract

Cited

Shared

Discussed